Patents by Inventor Kieu Lam
Kieu Lam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230372245Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: May 16, 2023Publication date: November 23, 2023Applicant: Arbutus Biopharma CorporationInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20230001021Abstract: The present disclosure provides, among other things, polynucleotide constructs, compositions, and methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need thereof a composition comprising a polynucleotide construct comprising a 5? UTR, a codon optimized mRNA encoding an ornithine transcarbamylase, and a 3? UTR.Type: ApplicationFiled: October 22, 2020Publication date: January 5, 2023Inventors: Owen DALY, Kieu LAM, James HEYES, Richard HOLLAND, Christine ESAU, Ed YAWORSKI, Mary PRIEVE
-
Patent number: 11141378Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: April 12, 2021Date of Patent: October 12, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20210267895Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: April 12, 2021Publication date: September 2, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20210220274Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: November 10, 2020Publication date: July 22, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20200113832Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: May 24, 2019Publication date: April 16, 2020Inventors: Edward YAWORSKI, Kieu LAM, Lloyd JEFFS, Lorne PALMER, Ian MacLACHLAN
-
Publication number: 20180092848Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: December 13, 2017Publication date: April 5, 2018Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20180085312Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: August 7, 2017Publication date: March 29, 2018Applicant: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 9719435Abstract: Techniques for measuring cylinder pressure include receiving an analog cylinder pressure signal indicative of pressure in a cylinder of an engine and an angular position signal indicative of an angular position of the engine. The analog cylinder pressure signal is converted to a digital cylinder pressure signal by (i) windowing the analog cylinder pressure signal in the angle-domain using the angular position signal and (ii) sampling the windowed analog cylinder pressure signal in the time-domain, and the digital cylinder pressure signal is filtered in the time-domain to obtain a filtered digital cylinder pressure signal. A measured pressure in the angle domain is obtained by sampling the filtered digital cylinder pressure signal using the angular position signal, and operation of the engine is controlled using the measured cylinder pressure.Type: GrantFiled: May 11, 2015Date of Patent: August 1, 2017Assignee: FCA US LLCInventors: Jacob Andrew Kohn, Dung Kieu Lam
-
Publication number: 20170042814Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: May 25, 2016Publication date: February 16, 2017Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: EDWARD YAWORSKI, KIEU LAM, LLOYD JEFFS, LORNE PALMER, IAN MacLACHLAN
-
Publication number: 20160333805Abstract: Techniques for measuring cylinder pressure include receiving an analog cylinder pressure signal indicative of pressure in a cylinder of an engine and an angular position signal indicative of an angular position of the engine. The analog cylinder pressure signal is converted to a digital cylinder pressure signal by (i) windowing the analog cylinder pressure signal in the angle-domain using the angular position signal and (ii) sampling the windowed analog cylinder pressure signal in the time-domain, and the digital cylinder pressure signal is filtered in the time-domain to obtain a filtered digital cylinder pressure signal. A measured pressure in the angle domain is obtained by sampling the filtered digital cylinder pressure signal using the angular position signal, and operation of the engine is controlled using the measured cylinder pressure.Type: ApplicationFiled: May 11, 2015Publication date: November 17, 2016Inventors: Jacob Andrew Kohn, Dung Kieu Lam
-
Patent number: 9364435Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: August 18, 2014Date of Patent: June 14, 2016Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20150164799Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: August 18, 2014Publication date: June 18, 2015Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 9005654Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid, is included in one of the buffer solution or the lipid solution. Upon mixing a liposome encapsulating the therapeutic product is substantially instantaneously formed. Thereafter the liposome solution formed is immediately diluted with buffer solution to enhance homogeneity and maintain small particle size.Type: GrantFiled: July 27, 2006Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Edward Yaworski, Kieu Lam
-
Patent number: 8822668Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: June 26, 2013Date of Patent: September 2, 2014Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20140065228Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 26, 2013Publication date: March 6, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 8492359Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: October 5, 2011Date of Patent: July 23, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20120183581Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: October 5, 2011Publication date: July 19, 2012Applicant: Protiva Biotherapeutics, IncInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 8058069Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: April 15, 2009Date of Patent: November 15, 2011Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20100130588Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: April 15, 2009Publication date: May 27, 2010Applicant: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan